Media

December 2022

Vator (Dec. 5, 2022)
No Camels (Dec. 5, 2022)
Precision Oncology News  (Dec. 1, 2022)
Clinical Trials Arena (Dec. 1, 2022)
Tech Funding News (Dec. 1, 2022)
The Capital Quest (Dec. 1, 2022)


November 2022

HIT Consultant Media: Nectin Therapeutics Raises $25M for Immuno-Oncology Therapies (Nov. 30, 2022)
Globes: Israeli co Nectin Therapeutics raises $25m – Globes (Nov. 30, 2022)
CTech: CTech Newsletter on LinkedIn (Nov. 30, 2022)
Becker’s Hospital Review: MD Anderson VC arm joins $25M funding round for cancer drug company (Nov. 30, 2022)
BioSpace: Nectin’s Series A Hits $25M as Investors Support New Target for Solid Tumors | BioSpace (Nov. 30, 2022)
Calcalist: חברת Nectin Therapeutics גייסה 25 מיליון דולר לטיפול בחולי סרטן (Nov. 30, 2022)
Calcalist: Nectin Therapeutics raises $25 million Series A to treat advanced cancer tumors
Jerusalem Post: Israeli biotech company begins trial for cancer immuno-oncology solution (Nov. 30, 2022)
PR Newswire: Nectin Therapeutics Announces Extended Series A Financing to Over $25M and Initiation of Patient Dosing in Phase 1 Clinical Trial of NTX1088, First-in-Class Anti-PVR Targeted Immunotherapy for Treatment of Patients with Advanced Solid Tumors (Nov. 30, 2022)